Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Ixekizumab has known and some unexpected side effects.

Promising cancer treatments were found, but the manufacturer closed.

The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Tofacitinib taken by mouth helps treat hair loss in children.

Abatacept may help some people with alopecia areata regrow hair.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Efalizumab can cause unexpected excessive hair growth.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Tofacitinib may help regrow hair in alopecia areata patients.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Daclizumab may cause psoriasis-like skin problems in multiple sclerosis patients.

Biologics for severe asthma have known side effects, but some new risks need more study.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Upadacitinib improved multiple immune-related conditions in one patient.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.